|
|
|
|
|
Anileridine
drug data and news
Anileridine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Anileridine | ||
| Brand Names/Synonyms | Adopol; Alidine; Anileridina [Inn-Spanish]; Anileridine; Anileridine [Ban:Inn]; Anileridinum [Inn-Latin]; Apidol; Apodol; Leritin; Leritine; Nipecotan; Phthalylsulfathiazole; Sulfathalidine | ||
| Indication | For treatment and management of pain (systemic) and for use as an anesthesia adjunct. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Anileridine, a potent analgesic, is an analog of pethidine. Anileridine is useful for the relief of moderate to severe pain. It may also be used as an analgesic adjunct in general anesthesia in the same manner as meperidine to reduce the amount of anesthetic needed, to facilitate relaxation, and to reduce laryngospasm. In addition, anileridine exerts mild antihistaminic, spasmolytic and antitussive effects. Anileridine's main pharmacologic action is exerted on the CNS. Respiratory depression, when it occurs, is of shorter duration than that seen with morphine or meperidine when equipotent analgesic doses are used. | ||
| Mechanism Of Action | Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. | ||
| Anileridine News (When available) |
| ||
| Dosage Forms | LIQUID; TABLET | ||
| Drug_Category | Analgesics; Narcotics; Opiate Agonists; ATC:N01AH05 | ||
| Absorption | Anileridine is absorbed by all routes of administration. | ||
| Interactions |
Interactions for Anileridine: Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression. | ||
| Toxicity | Symptoms of overexposure include dizziness, perspiration, a feeling of warmth, dry mouth, visual difficulty, itching, euphoria, restlessness, nervousness and excitement have been reported. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | ethyl1-[2-(4-aminophenyl)ethyl]-4-phenyl-piperidine-4-carboxylate | ||
| Chemical Formula | C22H28N2O2 | ||
| Molecular Weight | 352.47 g/mol | ||
| Smiles String | CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3 | ||
| Melting Point | 83 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.384 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | > 95% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Anileridine.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00741 | ||
| CAS Registry Number | 144-14-9 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:152095 | ||
| PharmGKB ID | PA10249 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 10014 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |